- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Perspectives on the acceptability, appropriateness, feasibility, barriers, and facilitators from patients receiving cabotegravir + rilpivirine long-acting injectable treatment (CAB+RPV LA): interim results from the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_108; PSPs had high treatment satisfaction scores, the majority finding clinic wait time, recovery time, and treatment information appropriate and acceptable. At M1, 424 of 430 (98.6%) PSPs completed questionnaires; to date, 264 (61.4%) have completed M4 questionnaires.
- |||||||||| Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J, Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Dual therapies as a treatment of human immunodeficiency virus : the end of a paradigm ? (Pubmed Central) - Sep 11, 2021 In the past, some dual therapies were associated with a higher risk of selecting resistance mutations. Nevertheless, current and future dual regimens based on powerful drugs with a high genetic barrier are non-inferior to triple therapies and could become the future gold standard for HIV treatment.
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Cabenuva®: Differentiated service delivery and the community Pharmacists' roles in achieving UNAIDS 2030 target in Nigeria. (Pubmed Central) - Aug 20, 2021 It is therefore recommended that the Nigerian government embrace community pharmacy-led drug administration initiatives and embark on accredited training programmes for the profession in line with drug administration services. The government should also put in place necessary funding mechanisms for community pharmacists for the extra workload placed on them in administering injection drug formulation in their respective pharmacies.
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
New P4 trial: GLACIER: Study Using CABENUVA (clinicaltrials.gov) - Jul 28, 2021 P4, N=120, Not yet recruiting,
- |||||||||| Edurant (rilpivirine) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Cabotegravir/rilpivirine (Cabenuva) for HIV-1 infection. (Pubmed Central) - Jul 14, 2021 Providing PLWH and healthcare providers with novel modes of ART administration, enhancing individualisation of treatment, may facilitate the achievement of UNAIDS 95-95-95 objectives. No abstract available
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis. (Pubmed Central) - Jun 30, 2021 Our modelling suggests that injectable cabotegravir-rilpivirine offers potential benefits; however, to be a cost-effective option, its introduction might need to be carefully targeted to individuals with HIV who might otherwise have suboptimal adherence to ART. As data accumulate from trials and implementation studies, such findings can be incorporated into the model to better inform on the full consequences of policy alternatives.
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Review, Journal: Recent advances in long-acting nanoformulations for delivery of antiretroviral drugs. (Pubmed Central) - Jun 22, 2021 Cabenuva™ is recently approved by Health Canada containing LA cabotegravir+LA rilpivirine nanocrystals (ViiV healthcare) for once monthly administration by intramuscular route...Moreover, it expatiates on application of profuse nanoformulations for long-acting effect with promising preclinical discoveries and two clinical leads. To add on, utilization of physiology- based and mechanism-based pharmacokinetic modelling and in vivo animal models which could lead to enhanced safety and efficacy of LA nanoformulations in humans have been included.
- |||||||||| Vocabria (cabotegravir oral) / ViiV Healthcare, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Enrollment closed, Head-to-Head: SOLAR: A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY (clinicaltrials.gov) - Jun 18, 2021 P3, N=654, Active, not recruiting, No abstract available Recruiting --> Active, not recruiting
- |||||||||| Edurant (rilpivirine) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Enrollment open: More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents (clinicaltrials.gov) - Jun 8, 2021 P1/2, N=155, Recruiting, Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
How about Cabenuva? (Twitter) - Jun 2, 2021
- |||||||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
[VIRTUAL] Week 124 results of the randomized, open-label, Phase 3 FLAIR study evaluating long-acting cabotegravir + rilpivirine for treatment in adults with HIV-1 infection (ITT-E population) () - May 27, 2021 - Abstract #IASHIV2021IAS_HIV_603; P3 At W124, monthly CAB+RPV LA maintained virologic suppression in most participants; the safety and tolerability profile was consistent with prior W48/W96 results. These results demonstrate the durability of CAB+RPV LA as a well-tolerated, effective maintenance therapy.
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: First Extended-Release Injectable Drug Therapy for HIV. (Pubmed Central) - May 11, 2021 These results demonstrate the durability of CAB+RPV LA as a well-tolerated, effective maintenance therapy. Cabenuva-an injectable formulation of cabotegravir and rilpivirine and the first injectable complete therapy for adults with HIV-1-is now approved.It is administered once a month as two intramuscular injections following a month of treatment with the oral forms of these drugs.
- |||||||||| Edurant (rilpivirine) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Trial completion date, Trial primary completion date: More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents (clinicaltrials.gov) - May 6, 2021 P1/2, N=155, Active, not recruiting, Cabenuva-an injectable formulation of cabotegravir and rilpivirine and the first injectable complete therapy for adults with HIV-1-is now approved.It is administered once a month as two intramuscular injections following a month of treatment with the oral forms of these drugs. Trial completion date: Apr 2026 --> Jul 2025 | Trial primary completion date: May 2022 --> Dec 2022
- |||||||||| Clinical, Review, Journal: Risks and benefits of reducing the number of drugs to treat HIV-1 infection. (Pubmed Central) - Apr 30, 2021
Some two-drug regimens, especially those including maraviroc, have not been as successful. Long-term safety issues of these two-drug regimens remain to be determined, but with the overwhelming evidence available in virological control and short-term safety compared to three-drug regimens, the potential benefits of some of these two-drug regimens appear to outweigh the risks.
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
New trial: Cabenuva Injection Tracking in CHORUS (clinicaltrials.gov) - Apr 27, 2021 P=N/A, N=43, Enrolling by invitation,
- |||||||||| Edurant (rilpivirine) / J&J, Rekambys (rilpivirine LA) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
[VIRTUAL] WEIGHT AND LIPID CHANGES IN PHASE 3 CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING TRIALS () - Mar 18, 2021 - Abstract #CROI2021CROI_715; Since InSTI-associated weight changes have only recently emerged, collection of weight data across the CAB development program was not standardized at sites and limited metabolic data were collected. Future and on-going studies will further characterize potential InSTI-associated weight gain and metabolic perturbations.
- |||||||||| Vocabria (cabotegravir oral) / ViiV Healthcare, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Trial completion date, Head-to-Head: SOLAR: A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY (clinicaltrials.gov) - Mar 12, 2021 P3, N=654, Recruiting, Future and on-going studies will further characterize potential InSTI-associated weight gain and metabolic perturbations. Trial completion date: Mar 2023 --> Jun 2023
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Vocabria : 795,46 $ CAD Cabenuva (600/900, first month) : 2418,75 $ CAD Cabenuva (400/600, other months) : 1209,37 $ CAD (Twitter) - Jan 22, 2021
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Review, Journal: Cabotegravir Plus Rilpivirine: First Approval. (Pubmed Central) - Jan 2, 2021 Based on the results of the ATLAS and FLAIR trials, the regimen was recently approved in Canada for the treatment of HIV-1 infection in adults to replace current antiretroviral therapy in patients who are virologically stable and suppressed. This article summarizes the milestones in the development of co-packaged cabotegravir and rilpivirine leading to this first approval.
- |||||||||| Vocabria (cabotegravir oral) / ViiV Healthcare, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Enrollment closed: Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants (clinicaltrials.gov) - Dec 3, 2020 P1, N=15, Active, not recruiting, This article summarizes the milestones in the development of co-packaged cabotegravir and rilpivirine leading to this first approval. Recruiting --> Active, not recruiting
- |||||||||| Vocabria (cabotegravir oral) / ViiV Healthcare, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Enrollment open, Head-to-Head: SOLAR: A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY (clinicaltrials.gov) - Dec 3, 2020 P3, N=654, Recruiting, Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
|